Blog

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles/ruberinternacional.es

Feb 6, 2025, 15:29

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared an article Minjung Bak and colleagues authored on X:

“Cardiotoxicity of osimertinib is real. In this Korean study, osimertinib-related cardiotoxicity was 4.7%, including 3.4% requiring cardiologic intervention. Age and previous heart conditions identified. Implications for long-lasting treatment.”

Antonio Calles

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population

Authors: Minjung Bak et al.

Antonio Calles: Cardiotoxicity of osimertinib is real

Antonio Calles cancer Eun Kyoung Kim Hyukjin Park Hyun Ae Jung Jihoon Kim Jin Seok Ahn Jinhyun Cho Minjung Bak Myung-Ju Ahn Nuri Lee OncoDaily Oncology Sang-Chol Lee Se-Hoon Lee Sehhoon Park Seung Woo Park Sung-A Chang Sung-Ji Park

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers